// App-Quantinova.ai

: A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Researchers

Presenter

  • Wojciech Jurczak

Principal Investigators

  • Simon Rule

  • William Townsend

  • David Tucker

  • Barbara Sarholz

  • Jrgen Scheele

  • John G. Gribben

  • Pier Luigi Zinzani

Medical Centers

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Department of Haematology, Plymouth University Medical School, Plymouth, United Kingdom

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

  • Department of Haematology, Royal Derby Hospital, Derby, United Kingdom

  • R&D Global Biostatistics & Epidemiology, Merck KGaA, Darmstadt, Germany

  • Global Evidence and Value Department, Merck KGaA, Darmstadt, Germany

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Istituto di Ematologia, Bologna, Italy

Locations

  • Poland

  • United Kingdom

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Adaptive

  • Dose Escalation

  • First-In-Human

Phase

  • I/II

Study Id's

  • NCT02825836

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved